#drug therapy — Friday, May 29, 2026 (1 items)
| 0 | 💬 0 |
Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial.
(linkinghub.elsevier.com)
|
Lancet Infectious Diseases 2026-05-29 | #amr #clinical trial #drug therapy #tb |